ALX Oncology (NASDAQ:ALXO) Releases Earnings Results

ALX Oncology (NASDAQ:ALXO) posted its earnings results on Thursday. The company reported ($0.76) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.77) by $0.01, Zacks reports.

ALX Oncology Stock Down 0.8 %

ALXO stock traded down $0.02 during trading on Friday, reaching $2.61. The stock had a trading volume of 1,577,240 shares, compared to its average volume of 806,314. ALX Oncology has a one year low of $2.45 and a one year high of $17.83. The company has a quick ratio of 5.21, a current ratio of 5.21 and a debt-to-equity ratio of 0.06. The company’s 50 day moving average is $6.35 and its two-hundred day moving average is $11.46. The company has a market capitalization of $135.98 million, a price-to-earnings ratio of -0.70 and a beta of 1.06.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on ALXO. Lifesci Capital cut shares of ALX Oncology from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, July 31st. HC Wainwright reissued a “buy” rating and issued a $25.00 price objective on shares of ALX Oncology in a research note on Thursday, August 1st. Stifel Nicolaus reissued a “hold” rating and issued a $3.00 price objective (down previously from $5.00) on shares of ALX Oncology in a research note on Friday. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of ALX Oncology in a research note on Wednesday, May 29th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $17.83.

Insiders Place Their Bets

In other news, insider Sophia Randolph sold 12,000 shares of the stock in a transaction that occurred on Monday, May 13th. The shares were sold at an average price of $15.94, for a total transaction of $191,280.00. Following the completion of the transaction, the insider now directly owns 330,349 shares of the company’s stock, valued at approximately $5,265,763.06. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, insider Sophia Randolph sold 12,000 shares of the firm’s stock in a transaction that occurred on Monday, May 13th. The shares were sold at an average price of $15.94, for a total value of $191,280.00. Following the completion of the transaction, the insider now directly owns 330,349 shares of the company’s stock, valued at approximately $5,265,763.06. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Jaume Pons sold 20,000 shares of the firm’s stock in a transaction that occurred on Thursday, July 11th. The stock was sold at an average price of $7.90, for a total transaction of $158,000.00. Following the completion of the transaction, the insider now directly owns 593,447 shares of the company’s stock, valued at $4,688,231.30. The disclosure for this sale can be found here. In the last ninety days, insiders sold 58,469 shares of company stock valued at $554,946. Corporate insiders own 33.40% of the company’s stock.

ALX Oncology Company Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.